Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Table 7 Comparative summary of GVHD frequencies and clinical outcomes in selected studies for HLA-match sibling myeloablative hsct

	Our results n = 508	Tanimoto et al. [[5]] n = 509	Couban et al. [[3]] n = 109	Schmitz et al. [[4]] n = 163	Bensinger et al. [[2]] n = 81	Yang et al. [[24]] n = 68	Ringde′n et al.[[25]] n = 1887
GVHD prophylaxis regimen	MMF + CSA + MTX	CSA + MTX	CSA + MTX	CSA + MTX	CSA + MTX	CSA + MTX	CSA ± MTX
2-4 aGVHD(%)	23	32 ~ 37	44	52	64	46	37 ~ 46
3-4 aGVHD(%)	10	9 ~ 18	26	28	15	9	26 ~ 38
cGVHD(%)	67	42 ~ 62	85	67	46	45	26 ~ 38
extensive cGVHD(%)	45	27 ~ 42	40	ns	37	ns	ns
OS(%)	71*	74*	68*	65*	66*	68	ns
LFS(%)	70*	65 ~ 68*	ns	ns	65	62	33 ~ 49
NRM(%)	18	16 ~ 19	ns	ns	21	ns	25 ~ 38

*Standard risk patients.
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HLA, human leukocyte antigen; HCST, hematopoietic stem cell transplantation; NRM, non-relapse mortality; LFS, leukemia free survival; OS, overall survival; CsA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil.